Lyka Labs Ltd

₹ 58.3 1.23%

29 May - close price

About

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages^[1]

Key Points

Business Overview:^[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.

Website BSE NSE

Market Cap ₹ 208 Cr.
Current Price ₹ 58.3
High / Low ₹ 126 / 44.1
Stock P/E
Book Value ₹ 24.4
Dividend Yield 0.00 %
ROCE -4.45 %
ROE -8.88 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company's working capital requirements have reduced from 33.1 days to 17.4 days

Cons

Company has low interest coverage ratio.
Company has a low return on equity of -1.24% over last 3 years.
Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	19	21	27	31	27	30	41	33	31	29	33	31	28
	17	19	23	26	25	26	36	28	27	26	36	29	33
Operating Profit	3	3	4	6	2	4	5	5	3	3	-3	2	-4
OPM %	14%	12%	15%	19%	8%	13%	13%	15%	11%	12%	-10%	6%	-16%
	0	0	0	1	0	1	0	1	1	1	1	1	-22
Interest	3	1	1	1	1	1	1	1	1	1	1	1	1
Depreciation	3	3	3	3	3	2	2	2	1	2	2	2	2
Profit before tax	-3	-2	-0	2	-1	2	3	4	2	1	-5	0	-30
Tax %	2%	2%	-34%	43%	33%	26%	24%	25%	44%	31%	-24%	0%	-0%
	-3	-2	-0	1	-2	2	2	3	1	1	-4	0	-30
EPS in Rs	-0.98	-0.52	-0.09	0.41	-0.49	0.49	0.69	0.76	0.34	0.23	-1.02	0.08	-8.34
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2015	Mar 2016 9m	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	90	57	78	42	41	41	62	164	81	106	135	121
	72	49	56	42	40	44	48	67	65	92	117	123
Operating Profit	18	8	22	-1	1	-3	14	98	16	15	18	-2
OPM %	20%	14%	28%	-1%	2%	-8%	23%	59%	19%	14%	13%	-2%
	5	11	-0	3	2	-25	1	-2	-4	2	2	-19
Interest	18	11	17	8	6	19	26	20	12	5	2	3
Depreciation	4	3	6	6	4	8	8	15	14	12	6	8
Profit before tax	1	5	-1	-11	-7	-55	-18	60	-13	-1	11	-33
Tax %	0%	0%	-66%	-3%	-124%	0%	-21%	34%	1%	143%	28%	-3%
	1	5	-0	-11	2	-55	-14	40	-13	-2	8	-32
EPS in Rs	0.63	2.19	-0.09	-3.85	0.61	-19.31	-5.04	13.91	-4.33	-0.69	2.31	-9.05
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	8%
5 Years:	14%
3 Years:	14%
TTM:	-10%

Compounded Profit Growth
10 Years:	%
5 Years:	4%
3 Years:	-25%
TTM:	-220%

Stock Price CAGR
10 Years:	-2%
5 Years:	-4%
3 Years:	-15%
1 Year:	-53%

Return on Equity
10 Years:	-2%
5 Years:	8%
3 Years:	-1%
Last Year:	-9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	22	22	22	28	28	29	29	29	31	33	36	36
Reserves	38	43	52	69	70	-10	-24	16	46	66	99	51
	109	106	112	102	91	137	163	129	74	59	39	49
	64	57	57	46	59	66	46	35	28	28	31	35
Total Liabilities	233	228	243	245	249	221	213	209	179	186	206	171
	62	60	86	81	76	102	95	90	66	56	84	87
CWIP	27	30	24	26	30	26	24	18	16	23	1	2
Investments	63	63	62	62	62	32	32	32	32	32	32	0
	82	75	70	75	80	61	61	68	65	75	88	82
Total Assets	233	228	243	245	249	221	213	209	179	186	206	171

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	29	8	20	7	18	-11	6	77	7	3	3	5
	30	5	-5	-3	-3	0	0	-4	7	-9	-13	-9
	-63	-13	-15	-4	-16	20	-8	-63	-20	3	5	4
Net Cash Flow	-3	0	-0	-1	-0	8	-2	9	-7	-3	-5	-0
Free Cash Flow	57	3	15	3	15	-12	4	71	13	-6	-10	-6
CFO/OP	163%	98%	98%	-1,400%	1,817%	381%	45%	79%	47%	31%	35%	-231%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	116	169	113	265	263	59	58	39	78	88	110	99
Inventory Days	90	74	93	124	98	99	67	97	87	81	86	109
Days Payable	283	323	283	536	519	430	301	109	103	93	95	135
Cash Conversion Cycle	-77	-80	-76	-147	-159	-272	-176	26	62	77	100	74
Working Capital Days	-313	-491	-398	-768	-172	-296	-154	-137	16	28	54	17
ROCE %	9%	9%	10%	-3%	-0%	-5%	5%	50%	3%	3%	8%	-4%

Insights

In beta

Jun 2015

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Number of Permanent Employees
count

xxx	xxx	xxx	xxx	xxx	xx	xxx	xxx		xxx
xx.xx	xx.xx	xx.xx	x.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx		x.xx
	xx.xx	xx.xx	xx.xx	xx.xx	xxx.xx	xxx.xx	xxx.xx
xxx	xx		xxx		xx		xx		xx
xx	xx		x		xx		x		xx
					xx	xx	xx		xx
						x	xx	xxx
xx			xxx
xxx			xxx

Please log in to see hidden values.

R&D Expenditure Capitalized as Assets (Self-Generated)
INR Lakhs

Electricity Consumption per Million Pack Formulation
'000 kwh

Expected/Pending Product Registrations
count

New Product Registrations Received
count

Lyophilization Manufacturing Capacity Enhancement (Incremental)
% increase

Animal Healthcare Division Revenue Contribution
INR Million

Patents Filed (Cumulative)
count

Total Product Registrations In Force
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	54.58%	54.81%	54.81%	54.81%	58.11%	58.11%	58.11%	58.16%	58.16%	58.16%	58.16%	58.16%
	0.17%	0.18%	0.17%	0.17%	0.15%	0.15%	0.15%	0.24%	0.16%	0.17%	0.17%	0.29%
	0.41%	0.41%	0.62%	0.81%	0.75%	0.66%	0.66%	0.66%	0.66%	0.66%	0.66%	0.66%
	44.84%	44.61%	44.41%	44.21%	40.99%	41.08%	41.07%	40.93%	41.02%	40.99%	40.99%	40.89%
No. of Shareholders	27,202	26,652	26,422	25,717	25,716	28,943	29,099	28,472	28,189	27,743	27,155	26,727

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	23.99%	18.66%	18.13%	19.88%	19.88%	47.79%	51.00%	54.81%	58.16%	58.16%
	4.74%	3.57%	3.64%	3.50%	3.50%	1.12%	0.18%	0.17%	0.24%	0.29%
	1.70%	1.01%	1.01%	0.66%	0.47%	1.19%	3.74%	0.81%	0.66%	0.66%
	69.57%	76.75%	77.22%	75.96%	76.15%	49.89%	45.08%	44.21%	40.93%	40.89%
No. of Shareholders	19,769	20,791	20,281	19,642	19,350	26,220	26,820	25,717	28,472	26,727

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Lyka Labs Ltd

Lyka Labs Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Insights

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings